BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/30/2026 1:50:34 AM | Browse: 4 | Download: 2
 |
Received |
|
2026-04-30 01:19 |
|
Peer-Review Started |
|
2026-04-30 01:20 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2026-07-10 01:21 |
|
Revised |
|
2026-07-13 05:42 |
|
Publication Fee Transferred |
|
2026-07-27 01:56 |
|
Second Decision by Editor |
|
2026-08-31 03:15 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-08-31 08:11 |
|
Articles in Press |
|
2026-08-31 08:11 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-09-17 02:51 |
|
Publish the Manuscript Online |
|
2026-09-30 01:50 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Randomized Controlled Trial |
| Article Title |
Add-on trimebutine-maleate does not improve tolerability or eradication in bismuth quadruple therapy for Helicobacter pylori
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Eun Jeong Gong and Chang Seok Bang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Samil Pharmaceutical Company |
|
|
| Corresponding Author |
Chang Seok Bang, MD, PhD, Department of Internal Medicine, Hallym University College of Medicine, Sakju-ro 77, Chuncheon 24253, Gangwon-do, South Korea. cloudslove@naver.com |
| Key Words |
Helicobacter pylori; Eradication therapy; Bismuth quadruple therapy; Trimebutine; Adverse events |
| Core Tip |
This is the first prospective randomized controlled trial to evaluate add-on trimebutine maleate as an adjuvant to 14-day bismuth quadruple therapy for Helicobacter pylori eradication. Despite trimebutine’s widespread off-label use, add-on treatment did not reduce treatment-emergent adverse events, improve medication adherence, or increase eradication rates, with point estimates tightly clustered around the null. Although the trial was underpowered owing to early termination, these findings do not support routine adjunctive use of trimebutine and redirect attention toward mucosa- and microbiota-directed strategies with proven benefit. |
| Publish Date |
2026-09-30 01:50 |
| Citation |
Gong EJ, Bang CS. Add-on trimebutine-maleate does not improve tolerability or eradication in bismuth quadruple therapy for Helicobacter pylori. World J Gastroenterol 2026; 32(44): 122850
|
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i44/122850.htm |
| DOI |
https://doi.org/10.3748/wjg.122850 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
